Roivant Sciences Ltd. $ROIV is Foursixthree Capital LP’s 7th Largest Position

Foursixthree Capital LP raised its position in Roivant Sciences Ltd. (NASDAQ:ROIV) by 4.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 938,175 shares of the company’s stock after acquiring an additional 38,175 shares during the quarter. Roivant Sciences accounts for about 3.9% of Foursixthree Capital LP’s investment portfolio, making the stock its 7th largest holding. Foursixthree Capital LP owned approximately 0.14% of Roivant Sciences worth $14,195,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the company. Goldman Sachs Group Inc. boosted its stake in shares of Roivant Sciences by 15.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company’s stock valued at $24,553,000 after purchasing an additional 324,764 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Roivant Sciences by 1.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company’s stock worth $24,678,000 after buying an additional 34,341 shares during the period. Envestnet Asset Management Inc. increased its stake in Roivant Sciences by 30.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 42,810 shares of the company’s stock worth $482,000 after buying an additional 9,936 shares during the period. PNC Financial Services Group Inc. lifted its holdings in Roivant Sciences by 36.0% in the 2nd quarter. PNC Financial Services Group Inc. now owns 13,934 shares of the company’s stock worth $157,000 after buying an additional 3,686 shares in the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in Roivant Sciences by 7.5% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 108,166 shares of the company’s stock valued at $1,219,000 after buying an additional 7,531 shares during the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Insider Transactions at Roivant Sciences

In related news, CFO Richard Pulik sold 406,731 shares of the business’s stock in a transaction dated Tuesday, December 23rd. The stock was sold at an average price of $22.43, for a total value of $9,122,976.33. Following the completion of the sale, the chief financial officer directly owned 239,413 shares of the company’s stock, valued at $5,370,033.59. The trade was a 62.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Frank Torti sold 1,400,000 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $27.42, for a total value of $38,388,000.00. Following the sale, the insider owned 13,736,547 shares in the company, valued at $376,656,118.74. The trade was a 9.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 8,274,269 shares of company stock valued at $205,891,471 over the last ninety days. 10.80% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several analysts have recently weighed in on ROIV shares. Citigroup raised their target price on Roivant Sciences from $26.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, February 10th. The Goldman Sachs Group increased their price target on Roivant Sciences from $24.00 to $33.00 and gave the company a “buy” rating in a report on Monday, December 15th. TD Cowen restated a “buy” rating on shares of Roivant Sciences in a research note on Wednesday, March 4th. Leerink Partners lifted their price objective on Roivant Sciences from $29.00 to $32.00 and gave the stock an “outperform” rating in a report on Monday, December 15th. Finally, Weiss Ratings lowered Roivant Sciences from a “hold (c-)” rating to a “sell (d)” rating in a research report on Monday, February 9th. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $28.81.

Roivant Sciences Stock Performance

ROIV opened at $28.06 on Monday. The company has a 50-day moving average of $25.29 and a 200-day moving average of $20.76. The company has a market capitalization of $20.08 billion, a P/E ratio of -23.98 and a beta of 1.17. Roivant Sciences Ltd. has a 1-year low of $8.73 and a 1-year high of $30.33.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.